GENXONE S.A. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.18 PLN | +1.98% |
|
+3.00% | +14.87% |
| May. 13 | GenXone S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Feb. 12 | GenXone S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Sales 2021 | 23.2M 5.88M | Sales 2022 | 10.59M 2.68M | Capitalization | 33.67M 8.53M |
|---|---|---|---|---|---|
| Net income 2021 | 8M 2.03M | Net income 2022 | - 0 | EV / Sales 2021 | 2.37 x |
| Net cash position 2021 | 14.23M 3.61M | Net cash position 2022 | 11.16M 2.83M | EV / Sales 2022 | 2.13 x |
| P/E ratio 2021 |
7.89
x | P/E ratio 2022 |
70.2
x | Employees | 20 |
| Yield 2021 |
4.76% | Yield 2022 |
-
| Free-Float | 46.59% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.98% | ||
| 1 week | +3.00% | ||
| 1 month | -12.96% | ||
| 3 months | -10.95% | ||
| 6 months | +0.65% | ||
| Current year | +14.87% |
1 week
6.06
6.30
1 month
5.707.26
Current year
5.468.36
1 year
5.009.80
3 years
5.0034.50
5 years
5.0076.00
10 years
5.0076.00
| Managers | Title | Age | Since |
|---|---|---|---|
Michal Kaszuba
CEO | Chief Executive Officer | - | 15-12-31 |
| Chief Operating Officer | - | 15-12-31 | |
Lukasz Krych
CTO | Chief Tech/Sci/R&D Officer | - | 17-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mariusz Koitka
BRD | Director/Board Member | 59 | - |
Janusz Krasniak
BRD | Director/Board Member | 59 | - |
Dariusz Zowczak
BRD | Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 6.18 | +1.98% | 2,527 |
| 24-05-29 | 6.06 | -3.81% | 462 |
| 24-05-28 | 6.3 | +2.61% | 75 |
| 24-05-27 | 6.14 | +2.33% | 504 |
End-of-day quote Warsaw S.E., May 30, 2024
More quotes
Genxone SA is a Poland-based company, which specializes in NGS (next generation sequencing) and medical diagnostics. The Company is involved in the development and marketing of nanoforming technology in the field of science, business and medicine and cooperates as a commercial partner with Oxford Nanopore Technologies - biotechnological innovation entity.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +14.87% | 5.17M | |
| +15.72% | 78.51B | |
| +13.10% | 9B | |
| +58.17% | 4.96B | |
| -14.94% | 4.84B | |
| -.--% | 3.72B | |
| +20.25% | 2.48B | |
| -26.63% | 2.19B | |
| +16.75% | 2.12B | |
| -37.97% | 1.94B |
- Stock Market
- Equities
- GX1 Stock
